Drug Trial Radar · NCT07499544
A Phase III Study to Evaluate the Efficacy and Safety of Libevitug in Participants With Chronic HDV Infection (D-clear Study)
Last checked: Nov 19, 2026Latest source record: Aug 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
160
Planned (sponsor's estimate)
Start
Apr 22, 2026
Primary completion
Sep 12, 2028
Study completion Jan 29, 2030
Sponsor
- Lead sponsor
- Huahui HealthIndustry
- Sponsor type
- Industry
- First posted
- Mar 30, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an international, multicenter, randomized, controlled, open-label Phase III trial. It will evaluate the efficacy and safety of libevitug in participants with chronic HDV infection.
Conditions
- Chronic Hepatitis D Infection
Interventions
Libevitug 20 mg/kgDrug
Route of administration: intravenous infusion
Libevitug 10 mg/kgDrug
Route of administration: intravenous infusion
Delayed treatment with libevitugOther
Route of administration: intravenous infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of participants with HDV RNA below LLOQ with TND or a decrease of ≥ 2 log10 from baseline, and ALT normalization at Week 48 of the treatment periodTime frame: Week 48
Locations
7 sites in 3 countries. Site status is shown where the registry gives one.
Site 201
Garden Grove, California · Recruiting
Site 101
Changchun, Jilin, China · Recruiting
Site 104
Kashgar, Xinjiang Uygur Autonomous Region, China · Recruiting
Site 103
Ürümqi, Xinjiang Uygur Autonomous Region, China · Recruiting
Site 303
Rawalpindi, Punjab Province, Pakistan · Recruiting
Site 301
Karachi, Sindh, Pakistan · Recruiting
Site 302
Karachi, Sindh, Pakistan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.